Abelacimab - Anthos Therapeutics
Alternative Names: anti-FXI mAb; FXI antibody; MAA-868Latest Information Update: 12 Jun 2024
At a glance
- Originator Novartis Pharmaceuticals
- Developer Anthos Therapeutics; Labcorp Drug Development; Novartis Pharmaceuticals; TIMI Study Group
- Class Antiarrhythmics; Anticoagulants; Antithrombotics; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Factor XI inhibitors; Factor XIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Atrial fibrillation; Venous thromboembolism
- Phase II Stroke; Thrombosis
Most Recent Events
- 06 Jun 2024 Data Monitoring Committee recommends an open-label extension for abelacimab
- 18 Nov 2023 Phase-III clinical trials in Atrial fibrillation (In the elderly) in Brazil, Bulgaria, Chile, Germany, Hungary, Italy, Poland, Romania, Spain, United Kingdom (SC) (NCT05712200)
- 12 Nov 2023 Efficacy data from a phase II AZALEA-TIMI 71 trial in Stroke released by Anthos Therapeutics